September 2 - 5, 2021 Virtual Conference
![]() |
![]() |
![]() |
![]() |
P-01 | Temporal and Spatial Dynamics of Hepatic Stellate Cell Activation in Intrahepatic Cholangiocarcinoma | Liqin Zhu | ![]() |
![]() |
|||
P-02 | Intra-tumoral epigenetic heterogeneity and aberrant molecular clocks in hepatocellular carcinoma | Paula Restrepo | ![]() |
![]() |
|||
P-03 | Autoimmunity and cancer immunosurveillance in the biliary tree | Jonathan Pol | ![]() |
![]() |
|||
P-04 | Inflamed class of HCC: an expansion of the immune class based upon new molecular features | Josep M. Llovet | ![]() |
![]() |
|||
P-05 | Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma. | Petros Fessas | ![]() |
![]() |
|||
P-06 | New therapeutic targets in cisplatin-resistant hepatoblastoma | Théo Hirsch | ![]() |
![]() |
|||
P-07 | Notch Pathway Activation Drives Immune Evasion in Hepatocellular Carcinoma | Katherine Lindblad | ![]() |
![]() |
|||
P-09 | Deep sequencing of HCC endothelium reveals an active role in immunosuppression and highlights the ectonucleotidase CD73 as a potential therapeutic target. | Rosemary Faulkes | ![]() |
![]() |
|||
P-10 | Activating Mucosal-Associated Invariant T cells (MAITs) in vivo as a Novel Target for Liver Cancer Immunotherapy | Benjamin Ruf | ![]() |
![]() |
|||
P-11 | The TUMOR SUPPRESOR ROLE OF THE a1-Na/K-ATPase/Src-p/PI3K SIGNALOSOME in NASH Related Hepatocellular Carcinoma: A TRANSLATIONAL STUDY. | Juan Sanabria | ![]() |
![]() |
|||
P-12 | Interplay between EZH2 and OGT in hepatocellular carcinoma | Margot Thirion | ![]() |
![]() |
|||
P-14 | Molecular characterization of HCC in Mongolia delineates unique genomic features | Laura Torrens | ![]() |
![]() |
|||
P-15 | Exogenous Antioxidants, N-acetylcysteine and Glutathione, Enhance Cancer Initiation and Growth in Hepatocellular Carcinoma | Vanilla Xin Zhang | ![]() |
![]() |
|||
P-16 | Dual mechanisms mediated by specific transcription factors and RalGAPA2 activates RalA signaling to support HCC development | LU TIAN | ![]() |
![]() |
|||
P-17 | Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. | David Pinato | ![]() |
![]() |
|||
P-18 | Portal vein thrombosis in HCC patients infected with COVID-19 | Mohamed Elgazzar | ![]() |
![]() |
|||
P-19 | Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma | Jordi Abril-Fornaguera | ![]() |
![]() |
|||
P-20 | Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver: A Spanish multicentre study | Marta Romero-Gutiérrez | ![]() |
![]() |
|||
P-21 | PROGNOSIS OF PATIENTS WITH OTHER PRIMARY TUMORS ASSOCIATED TO HEPATOCELULLAR CARCINOMA. | Miriam Celada | ![]() |
![]() |
|||
P-22 | Geographic, linguistic, and cultural factors are associated with clinical presentation, receipt of treatment, and survival of patients with hepatocellular carcinoma | Belaynew Taye | ![]() |
![]() |
|||
P-23 | Hepatic elastometry and risk of recurrence after HCC resection | PAULINE TORTAJADA | ![]() |
![]() |
|||
P-24 | Association of whole grains and dietary fiber intake with risk of liver cancer and chronic liver diseases in the NIH-AARP Diet and Health Study | Xing Liu | ![]() |
![]() |
|||
P-25 | Gene Set adaptation through graph generation enhances signature discrimination power and validates metabolism-related prognostic signatures in Hepatocellular Carcinoma | Josepmaria Argemi | ![]() |
![]() |
|||
P-26 | EXTERNAL VALIDATION OF THE INTEGRATED LIVER INFLAMMATORY SCORE (ILIS) AS A PROGNOSTIC INDEX IN PATIENTS WITH HEPATOCELLULAR CARCINOMA | Miriam Celada | ![]() |
![]() |
|||
P-28 | Undernutrition in patients with primary hepatocellular carcinoma | Hitomi Takada | ![]() |
![]() |
|||
P-29 | Dual filtration system for isolation and single cell RNA sequencing of circulating tumor cells and clusters in hepatocellular carcinoma: a pilot study | Vincent Chen | ![]() |
![]() |
|||
P-30 | The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma. | Ambreen Muhammed | ![]() |
![]() |
|||
P-31 | Clinicopathological characterization of steatohepatitic variant of hepatocellular carcinoma (SH-HCC). | Loc TRAPANI | ![]() |
![]() |
|||
P-34 | Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON | Masatoshi Kudo | ![]() |
![]() |
|||
P-35 | The Efficacy and Prognostic Factors of TACE Combined with Apatinib in the Treatment of BCLC stage C Hepatocellular Carcinomas | Weifu LV | ![]() |
![]() |
|||
P-36 | A Pilot Study of the combination of Immune Checkpoint Inhibition with Ablation in Subjects with Hepatocellular Carcinoma; an evaluation of Trans-arterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) | Rebecca Wetzel | ![]() |
![]() |
|||
P-37 | A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL. | Thomas Talbot | ![]() |
![]() |
|||
P-38 | Impact of metabolic syndrome and non-alcoholic fatty liver disease in outcomes and tolerance after percutaneous multibipolar radiofrequency ablation for early hepatocellular carcinoma | Thi Thu Nga Nguyen | ![]() |
![]() |
|||
P-41 | Early antibiotic exposure is not detrimental to response to immune checkpoint inhibitor therapy for hepatocellular carcinoma: evidence from an observational study. | Petros Fessas | ![]() |
![]() |
|||
P-42 | Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres followed by Gemcitabine plus Cisplatin for Treatment of Intra-hepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial | Stephen Lam CHAN | ![]() |
![]() |
|||
P-43 | The Number of Small Hepatocellular Carcinoma Nodules in Patients Listed for Liver Transplantation within the Alpha-Fetoprotein Score Is a Prognostic Risk Factor | Alina Pascale | ![]() |
![]() |
|||
P-45 | Real-world outcomes of patients with hepatocellular carcinoma treated with transarterial radioembolization: results from CIRT, a large European prospective multi-centre observational study | Frank Kolligs | ![]() |
![]() |
|||
P-46 | Exploratory Network Meta-analyses of Selective Internal Radiation Therapy versus Sorafenib, Lenvatinib, and Atezolizumab-Bevacizumab as First-line Treatment in Subgroups of Patients with Hepatocellular Carcinoma | Richard Pollock | ![]() |
![]() |
|||
P-47 | Previous/Concurrent Radiation Enhanced the Efficacy of Immunotherapy in Metastatic and Recurrent Liver Cancer: A Pilot Study from the Real-world Data | Bo Chen | ![]() |
![]() |
|||
P-48 | Progression patterns and clinical outcomes following immune checkpoint inhibition for hepatocellular carcinoma (HCC): a multi-institutional international study. | Thomas Talbot | ![]() |
![]() |
|||
P-49 | Identification of Regorafenib Prognostic index (REP index) via recursive partitioning analysis in Advanced Hepatocellular Carcinoma Patients Receiving systemic treatment. | margherita rimini | ![]() |
![]() |
|||
P-50 | Impact of previous surgery on prognosis in patients with cholangiocarcinoma under chemotherapy | margherita rimini | ![]() |
![]() |
|||
P-51 | Free Androgen Index Levels May Influence the Trans-arterial Chemoembolization with Doxorubicin-Eluting Beads Response in Hepatocellular Carcinoma Patients: Preliminary Results. | Silvia Acosta-Lopez | ![]() |
![]() |
|||
P-53 | A humanized Claudin-1-specific monoclonal antibody for treatment of hepatocellular carcinoma | Marion Muller | ![]() |
![]() |
|||
P-54 | Emerging role of circulating miR-23b-3p and tissue miR-193a-3p as potential innovative biomarkers for human hepatocellular carcinoma. | Ilaria Grossi | ![]() |
![]() |
|||
P-55 | Lifestyle changes in DAA-cured Hepatitis C patients with advanced liver disease included in a nurse-led liver cancer screening program | Gemma Iserte | ![]() |
![]() |
|||
P-57 | Early SARS-CoV-2-related mortality of liver cancer patients: Cancer stage matters. | Sergio Muñoz-Martínez | ![]() |
![]() |
|||
P-58 | Deciphering Liver Cancer Tissue Organization by 3D Electron Microscopy and machine learning | Christophe Grosset | ![]() |
![]() |
|||
P-59 | Low baseline plasma L-Glutamine concentration identifies hepatocellular carcinoma patients at high risk of developing early gastrointestinal adverse events during sorafenib treatment. | Loreto Boix | ![]() |
![]() |
|||
P-60 | Efficacy and Safety of Lenvatinib in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Retrospective Analysis | KyungHye Bang | ![]() |
![]() |
|||
P-61 | Novel management score of systemic therapy for hepatocellular carcinoma patients | Issei SAEKI | ![]() |
![]() |
September 2 - 5, 2021 Virtual Conference
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|